ANAB logo

ANAB
AnaptysBio Inc

2,045
Mkt Cap
$2.02B
Volume
460,269.00
52W High
$70.11
52W Low
$16.82
PE Ratio
-134.68
ANAB Fundamentals
Price
$70.10
Prev Close
$68.54
Open
$67.26
50D MA
$57.76
Beta
0.84
Avg. Volume
677,026.02
EPS (Annual)
-$0.4601
P/B
52.78
Rev/Employee
$2.26M
$1,373.19
Loading...
Loading...
News
all
press releases
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year High - Time to Buy?
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month High - Still a Buy...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
AnaptysBio (NASDAQ:ANAB) Trading Up 7.6% - Still a Buy?
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.6% - Still a Buy...
MarketBeat·5d ago
News Placeholder
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director John Schmid sold 20,645 shares of AnaptysBio stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $56.11, for a total value of $1,158,390.95. Following the sale, the director directly owned...
MarketBeat·9d ago
News Placeholder
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation...
MarketBeat·10d ago
News Placeholder
Piper Sandler Raises AnaptysBio (NASDAQ:ANAB) Price Target to $95.00
Piper Sandler lifted their target price on AnaptysBio from $67.00 to $95.00 and gave the stock an "overweight" rating in a report on Tuesday...
MarketBeat·11d ago
News Placeholder
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright
HC Wainwright reissued a "buy" rating and set a $66.00 target price on shares of AnaptysBio in a research report on Monday...
MarketBeat·12d ago
News Placeholder
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 17,679 Shares
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) CEO Daniel Faga sold 17,679 shares of the business's stock in a transaction on Friday, March 27th. The shares were sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the transaction, the chief executive officer...
MarketBeat·14d ago
News Placeholder
AnaptysBio (NASDAQ:ANAB) Board of Directors Authorizes Share Buyback Plan
AnaptysBio (NASDAQ:ANAB - Get Free Report) declared that its Board of Directors has approved a stock repurchase plan on Friday, March 27th, RTT News reports. The company plans to buyback $100,000.00 billion in outstanding shares. This buyback authorization permits the biotechnology company to...
MarketBeat·15d ago
News Placeholder
AnaptysBio (NASDAQ:ANAB) Shares Down 10.3% - Time to Sell?
AnaptysBio (NASDAQ:ANAB) Shares Down 10.3% - Should You Sell...
MarketBeat·15d ago
News Placeholder
AnaptysBio Authorizes $100 Mln Stock Repurchase Plan
(RTTNews) - AnaptysBio Inc. (ANAB), on Friday, announced that its board has authorized a stock repurchase plan of up to $100 million and provided a business update...
Nasdaq News: Markets·15d ago
<
1
2
...
>

Latest ANAB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.